sar425899 sanofi dual agonist glp-1 glucagon Transforming obesity: The advancement of multi-receptor drugs: Cell Focus on Glucagon-like Peptide-1 Target:
Description
Intention-to-treat analyses resulted in an HR of 1.36 (95% CI 0.51, 3.61)
Mean INR did not change (0.00
Metabolic Benefits: Along with weight loss, it has shown promising results in treating Type 2 diabetes, with some studies showing hemoglobin A1c reductions
The results of the PIONEER-3 trial have now been published in the renowned journal Journal of the American Medical Association (JAMA) and are said to be trend-setting for future therapy of type 2 diabetes.
